Physician

Alireza Abdolmohammadi, MD

According to 2025 Medicare claims, Alireza Abdolmohammadi, MD (NPI: 1871816207) practices medical oncology, with the plurality of this provider's patient population coming from Tuolumne, CA. This provider's primary affiliated billing organization is SONORA COMMUNITY HOSPITAL (NPI: 1891732418; TIN: 941415069) and primary practice location at 95370-5278.

Abdolmohammadi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 572 traditional Medicare patients, billed 4,237 HCPCS/CPT codes, and received $118,317 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 1,227 prescription claims across 355 beneficiaries totaling $2,420,372 in drug costs, led by Xtandi (Enzalutamide). DME data shows 77 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,546,849 to $2,420,372. For DME billing, reported payments moved up and down with repeated peaks and valleys, starting at $15,655 and ending at $49,044.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	602	2,211	$135,845
2016	679	2,268	$121,697
2017	765	3,022	$161,970
2018	781	3,110	$154,209
2019	857	3,180	$157,960
2020	950	3,696	$178,748
2021	882	3,071	$177,209
2022	918	3,433	$202,657
2023	955	3,268	$203,721
2024	572	4,237	$118,317

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	251	1,715	$1,546,849
2016	268	1,841	$2,326,399
2017	339	2,200	$2,640,889
2018	366	2,630	$3,910,277
2019	368	2,651	$5,008,580
2020	404	2,866	$5,185,938
2021	383	2,548	$5,202,465
2022	386	2,149	$4,219,480
2023	469	2,430	$5,790,704
2024	355	1,227	$2,420,372

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	85	409	$98,102
2016	69	303	$75,795
2017	64	623	$58,613
2018	60	423	$26,068
2019	105	411	$30,899
2020	95	520	$34,382
2021	N/R	101	$8,905
2022	12	125	$5,500
2023	50	126	$38,647
2024	N/R	77	$1,808

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	59	59	$123
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	19	19	$106
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	65	78	$98
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	366	816	$61
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	191	220	$34

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	47	1,470	$612,445
Brukinsa	Zanubrutinib	29	870	$267,379
Revlimid	Lenalidomide	11	294	$206,025
Inlyta	Axitinib	14	420	$189,362
Lenalidomide	Lenalidomide	13	329	$143,680

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	18	$694
J8700	Temozolomide, oral, 5 mg	N	N/R	21	$538
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	18	$339
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	20	$238

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for Alireza Abdolmohammadi, MD?

Tedicare shows public-source Medicare data for Alireza Abdolmohammadi, MD (NPI 1871816207), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Alireza Abdolmohammadi, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Alireza Abdolmohammadi, MD?

Alireza Abdolmohammadi, MD is linked to SONORA COMMUNITY HOSPITAL (billing NPI 1891732418) in the available physician profile data.

Does Alireza Abdolmohammadi, MD have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.